Jindřich Kopecký

Skilled Doctor with extensive experience in patient care, diagnosis and providing quality medical oncology services not only in hospital but also in hospice care. Adept at managing medical teams and resolving complex medical cases with utmost precision. Possesses outstanding organizational and communication skills.

• Czech Society for Oncology (member since 2009)
• European Society for Medical Oncology (ESMO) (member since 2013)
• Czech Society for Palliative Medicine (member since 2012)
• American Society of clinical oncology (ASCO) (member since 2019)
• European Association of Dermato Oncology (EADO) (member since 2017)
• European Organisation for Research and Treatment of Cancer (EORTC) (member since 2019)

• 11/2013, present, Teaching position – Undergraduate Study – Master's Degree, General Medicine, Clinical oncology, Charles University in Prague, Faculty of Medicine in Hradec Králové, Department of Clinical Oncology and Radiotherapy, Hradec Králové, Czech and Foreign Students
• 01/2014, present, Teaching Position - Undergraduate Study – Bachelor's Degree, Nurse care, Care in oncology, Charles University in Prague, Faculty of Medicine in Hradec Králové, Hradec Králové
• 11/2015, present, Teaching Position - Undergraduate Study – Master's Degree, Stomatology, Orofacial Pain, Charles University in Prague, Faculty of Medicine in Hradec Králové, Department of Stomatology, Hradec Králové, Czech and Foreign students

Principal investigator or sub-investigator in clinical trials both nationally and internationally.

CA209-9ER, Phase 3, CA209-914, Phase 3, CA209-214, Phase 3, Exelixis 313, Phase 3, MK6482-005 Phase 3, MK6485-022, Phase 3, MK6485-011, Phase 3, D508600001, Phase 3, CA 209-097T, Phase 3, SUNNIFORECAST, Phase 2, 0216-ASG - TITAN RCC, Phase 2, CPDR001F2301, Phase 3, CA209-915, Phase 3, CA209-238, Phase 3, HBI-8000-303, Phase 3, IOB012/IOB013, Phase 3, COLUMBUS AD study W00090GE303, Phase 3, CA224-098, Phase 3, CDRB436F2410, Phase 3, CA209-901, Phase 3, MK3475-B15, Phase 3, SGN22E-003, Phase 3

Based on Scopus data H index 13, number of cited works 50, number citations without self-citation 490

Based on Web of Science data H index 10, number of cited works 34 number citations without self-citation 362

• Kopecký J. et al. The outcome in patients with BRAF‐mutated metastatic melanoma treated with anti‐programmed death receptor‐1 monotherapy or targeted therapy in the real‐world setting Cancer Med. 2024 Mar; 13(5): e6982
• Kopecký J. et al. Prognostic value of blood cell count-derived ratios in BRAF-mutated metastatic melanoma. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2022 Dec;166(4):393-404
• Kopecký J. et al. Aplastic Anemia as a Cause of Death in a Patient with Glioblastoma Multiforme Treated with Temozolomide, Strahlentherapie und Onkologie, 2010, 186(8), 452-456
• Kopecký J. et al. Treatment possibilities of ipilimumab-induced thrombocytopenia-case study and literaure review, Japanese Journal of Clinical Oncology, 2015, 45(4), 381-384,
• Kopecký J. et al. Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors, In Vivo, 2021, 35(5), 2981-2990,
• Kopecký J. et al. Hemodiafiltration and plasma levels of axitinib in a patient with metastatic renal clear cell carcinoma, Biomedical Papers, 2018, 162(4), 335-339,
• Kopecký J. et al. Nivolumab induced encephalopathy in a man with metastatic renal celll cancer: a case report, Journal of Medical Case Reports, 2018, 12(1), 262,
• Kopecký J. et al. Hepatic Injury Induced by a Single Dose of Nivolumab - a Case Report and Literature Review, Klinická onkologie, 2019, 32(2), 133-138